Biohaven

Biohaven FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Biohaven (BHVN) as of Nov 12, 2026 is 82.58 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 69.29 % — a change of 19.18% (higher).

FCF Conversion

82.58 %

YoY

19.18%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Biohaven is 2025 82.58 % . FCF Conversion Rate (FCF/EBITDA) of Biohaven was 2024 69.29 % . It decreases by 19.18% higher compared to the previous year.

The Biohaven FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
83.56 USD
Jan 1, 2019
71.83 USD
Jan 1, 2020
66.28 USD
Jan 1, 2021
68.65 USD
Jan 1, 2022
59.40 USD
Jan 1, 2023
82.02 USD
Jan 1, 2024
69.29 USD
Jan 1, 2025
82.58 USD
The Biohaven FCF Conversion history
YEARFCF ConversionYoY
82.58 %+19.18%
69.29 %-15.52%
82.02 %+38.07%
59.40 %-13.47%
68.65 %+3.58%
66.28 %-7.73%
71.83 %-14.03%
83.56 %+80.19%
46.37 %-17.14%
55.96 %-30.16%
80.14 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biohaven Stock analysis

What does Biohaven do? Biohaven Pharmaceutical Holding Co. Ltd. generates revenue through the research and development of late-stage product candidates targeting neurological diseases and rare disorders. The company utilizes its glutamate platform to advance clinical-stage compounds for various indications, including trigriluzole for obsessive-compulsive disorder, spinocerebellar ataxia, and Alzheimer's disease. Additionally, the firm develops BHV-0223 for amyotrophic lateral sclerosis and BHV-5000 for conditions such as Rett syndrome, neuropathic pain, and treatment-resistant depression. The business model focuses on identifying and developing clinical-stage compounds that target orphan neurologic indications and other neurological pathways, with the company currently employing 825 full-time employees in New Haven, Connecticut. Biohaven is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biohaven stock

FCF Conversion Rate (FCF/EBITDA) of Biohaven is 82.58 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Biohaven changed from 69.29 % to 82.58 %, representing a 19.18% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Biohaven since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Biohaven with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Biohaven

All Key Metrics — Biohaven